CC-90009 + venetoclax + azacitidine

**CC-90009 + venetoclax + azacitidine** is a novel investigational combination regimen being studied for the treatment of **acute myeloid leukemia (AML)**. - **CC-90009 (eragidomide)** is a first-in-class cereblon E3 ligase modulator that selectively induces ubiquitination and proteasomal degradation of GSPT1, resulting in apoptosis of AML cells and reduction of leukemia stem cells[1][2][4][5]. - **Venetoclax** is a small molecule BCL-2 inhibitor that induces apoptosis by antagonizing BCL-2. - **Azacitidine** is a hypomethylating agent, which incorporates into DNA and RNA, causing DNA hypomethylation and cytotoxicity, leading to apoptosis in malignant cells. This combination therapy is being evaluated in phase 1b clinical trials for the safety and efficacy in patients with relapsed or refractory AML, including those harboring FLT3 mutations[5].

Other names

eragidomide + venetoclax + azacitidine